

REMARKS

Applicants acknowledge the examiner's finding that Claims 50-54, 68-109 are allowable over the prior art of record.

Claims 68, 74, 80, 81, 87, 93, 99, and new claims 110-124 are now pending in this application. These claims recite a group of five ureas in defining pharmaceutically acceptable salts and methods.

Claims 68, 74, 80, 81, 87, 93 and 99 are included in the claims that have been found to be allowable over the prior art. Claims 68 and 99 have not been amended. Claims 80, 81, 87 and 93 have been amended to be independent. The scope of claims 68, 74, 80, 81, 87, 93 and 99 has not changed and they remain allowable over the prior art.

New method Claim 110 contains language similar to the language of claim 74 but is directed to more general methods for treating cancerous cell growth. New method Claim 111 conforms to allowable method claim 99 but recites fewer salts (basic salts).

New method Claims 112-115 and 118-121 depend on allowable method claims 80, 81, 87 and 93. New method Claims 112-115 define basic salts as in claim 111 and new method Claims 118-121 define tosylate salts.

New composition Claims 122 and 123 depend on allowed composition claim 68 and define specific salts as recited in claims 74 and 99. New composition Claim 124 defines tosylate salts of the five ureas recited in claim 68.

Applicants submit the amended original claims and new claims are allowable over the prior art based on their similarity to previously allowed claims.

At this juncture, applicants prefer not to add to method claim 74 the "effective amount" feature which is inherent therein. As for the recitation of a "subject," this is also not necessary as the claim properly encompasses the recited treatment method scope.


Information Disclosure Statement

A new IDS has been submitted with this amendment.

In view of the above, favorable reconsideration is courteously requested. If there are any remaining issues which can be expedited by a telephone conference, the examiner is courteously invited to telephone counsel at the number indicated below.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,


Richard J. Traverso, Reg. No. 30,595
Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO &
BRANIGAN, P.C.
Arlington Courthouse Plaza 1, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: BAYER-25A

Date: July 27, 2004

(RJT/dm) K:\Bayer\25A\Reply to 1-27-04 OA.doc